An Open-Label Phase 1 Study to Investigate the Pharmacokinetics of Aldoxorubicin (INNO-206; DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors

Trial Profile

An Open-Label Phase 1 Study to Investigate the Pharmacokinetics of Aldoxorubicin (INNO-206; DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2014

At a glance

  • Drugs Aldoxorubicin (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors CytRx Corporation
  • Most Recent Events

    • 03 Jun 2014 Interim results (n=10) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 13 Aug 2013 Planned End Date changed from 1 Aug 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 21 May 2013 Initial results reported in a CytRx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top